Interviewed by Carey Powers of Powers & Company at the Glaucoma 360 New Horizons Forum 2025.
Archives for lrykardQlaris Bio Announces Positive Topline Data From Two Phase II Trials Of QLS-111 In Patients With Primary Open Angle Glaucoma And Ocular Hypertension
QLS-111 met all primary and secondary endpoints in the Osprey and Apteryx studies QLS-111 added to latanoprost drove up to 3.6 mmHg greater reduction in IOP as compared to latanoprost alone DEDHAM, Mass. — February 5, 2025 — Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results […]
Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class IOP-lowering Drug Candidate for Glaucoma
Financing led by Canaan and New Leaf Venture Partners, and includes funds managed by abrdn Inc., Correlation Ventures, and Mayo Clinic Ventures DEDHAM, Mass. — April 30, 2024 — Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has closed a $24 million Series B financing round. […]
Qlaris Bio’s Novel IOP-Lowering Product, QLS-111, Is Dosed In Phase II Trials
A first-in-class product, QLS‑111 is designed to lower intraocular pressure (IOP) beyond currently achievable levels in patients with glaucoma by targeting episcleral venous pressure (EVP) DEDHAM, Mass. — April 2, 2024 — Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing of two separate […]
An Interview With Dr. Shan Lin – Unmet Needs in Glaucoma & New Treatments On The Horizon
Please click below for an interview with Dr. Shan Lin, co-research director of the Glaucoma Center of San Francisco and a member of the Scientific Advisory Board of Qlaris Bio – Interviewed by Carey Powers of Powers & Company at the Glaucoma 360 New Horizons Forum 2024.